Technology
Health
Biotechnology

Cyclacel Pharmaceuticals

$0.75
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.1389 (22.26%) Today
-$0.013 (-1.70%) After Hours

Why Robinhood?

You can buy or sell CYCC and other stocks, options, ETFs, and crypto commission-free!

About

Cyclacel Pharmaceuticals, Inc. Common Stock, also called Cyclacel Pharmaceuticals, is a clinical-stage biopharmaceutical company. Read More It uses cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The company builds a diversified biopharmaceutical business, which is focused in hematology and oncology based on a pipeline of novel drug candidates. Its products include CYC065, seliciclib, and sapacitabine. The company was founded by Ronald J. Berenson, David Philip Lane, and David Glover on August 13, 1996 and is headquartered in Berkeley Heights, NJ.

Employees
14
Headquarters
Berkeley Heights, New Jersey
Founded
1996
Market Cap
7.80M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
257.03K
High Today
$1.02
Low Today
$0.705
Open Price
$0.8223
Volume
11.11M
52 Week High
$1.87
52 Week Low
$0.51

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Medical
Cancer Prevention
Pharmaceutical
US

News

NasdaqMay 8

Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results

223
Yahoo FinanceApr 29

Could Cyclacel Pharmaceuticals, Inc.'s (NASDAQ:CYCC) Investor Composition Influence The Stock Price?

Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who really controls Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), then you'll have to look at the makeup of its share registry. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. Warren Buffett said that he likes 'a business with enduring competitive advantages that is run by able and owner-ori...

189

Earnings

-$0.20
-$0.10
$0.01
$0.11
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.20 per share
Actual
-$0.14 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.